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Hypothalamic Prolactin Regulation of Luteinizing
Hormone Secretion in the Female Rat
Pasha Grachev, Xiao Feng Li, Vincent Goffin, and Kevin T. O’Byrne
Division of Women’s Health (P.G., X.F.L., K.T.O.), School of Medicine, King’s College London SE1 1UL,
United Kingdom; and INSERM Unité 1151 (V.G.), Faculté de Médecine, Institut Necker Enfants Malades,
75993 Paris, France
Prolactin (PRL) levels increase in response to long-term antipsychotic treatment that disrupts re-
productive function. Recent evidence suggests that activation of central PRL receptors (PRLR)
inhibits LH secretion and in ovariectomized rats. However, the mechanisms involved, the mode of
LH secretion affected and relevance to hyperprolactinemia remain unknown. We therefore in-
vestigated the contributionof central PRL/PRLR signaling to the controlof estradiol-induced surges
of LH and PRL and pulsatile LH secretion under basal and hyperprolactinemic conditions. First, by
subjecting ovariectomized estradiol-primed rats intracerebroventricularly administered with PRL
to frequent blood sampling,wedemonstrated that acute activationof hypothalamic PRLRdisrupts
pulsatile LH secretion. Pretreatment (intracerebroventricularly) with the pure PRLR antagonist,
1-9-G129R-hPRL, or the -aminobutyric acid receptor type A antagonist, bicuculline, blocked this
effect. Next, we revealed that sustained blockade of hypothalamic PRLR using 1-9-G129R-hPRL
augmented the magnitude of LH surges induced by estradiol benzoate and progesterone treat-
mentand suppressed theconcomitant surgesofPRL. Finally,wedetermined thatacuteantagonism
of central PRLR is insufficient to normalize the duration of the LH pulse interval prolonged as a
result of hyperprolactinemia induced by chronic exposure to the atypical antipsychotic sulpiride.
These data serve as the first evidence to suggest that PRL signaling through hypothalamic PRLR
inhibits pulsatile secretion of LH in a -aminobutyric acid receptor type A-dependent fashion and
tonically restrains the magnitude of the LH surge. Furthermore, our results indicate that transient
blockadeofhypothalamicPRL/PRLR signaling is notaneffective strategy for restoringLHpulsatility
perturbed by chronic hyperprolactinemia. (Endocrinology 156: 0000–0000, 2015)
Prolactin (PRL) is a peptide hormone with diverse reg-ulatory functions in the reproductive, nervous, and
immune systems. It derives its name from its involvement
in the control of lactation and mammary gland develop-
ment (1). The anterior pituitary is themajor origin of PRL
and contains abundant lactotropes, specialized cells that
secrete PRL into systemic circulation (2).Thebrain is akey
target of PRL; circulating PRL is actively transported
across the blood brain barrier into the cerebrospinal
fluid (CSF) by PRL receptor (PRLR)-expressing cells of
the choroid plexus (3). Furthermore, neural as well as
glial cells within circumventricular nuclei have been
shown to internalize and retain immunoreactive PRL
from the CSF (4).
The plethora of biological effects exerted by PRL are
initiated by the interaction between PRL and its receptor,
PRLR, which exists in long and short isoforms in humans
and rodents (5). The PRLR is an archetype of type 1 cy-
tokine receptors and comprises homodimerized single-
pass transmembrane chains of minimal complexity com-
pared to other family members (6). Upon PRL binding,
conformational changes occurringwithin the receptor ho-
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Abbreviations: aCSF, artificial CSF; ARC, arcuate nucleus; AVPV, anteroventral periven-
tricular nucleus;CSF, cerebrospinal fluid;D2R, dopamine type2 receptor; E2, 17-estradiol;
E2B, E2 benzoate; GABA, -aminobutyric acid; icv, intracerebroventricular; KNDy, kisspep-
tin/neurokinin B/dynorphinA; LC, locus coeruleus;OVX, ovariectomized; P4, progesterone;
PI3K, phosphatidylinositol-3-kinase; PRL, prolactin; PRLR, PRL receptor; pSTAT5, phos-
phorylated STAT5; SCN, suprachiasmatic nucleus; STAT5, signal transducer and activator
of transcription-5; TIDA, tuberoinfundibular dopaminergic.
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modimer trigger a combination of intracellular signaling
cascades including Janus kinase-2/signal transducer and
activator of transcription-5 (STAT5), Src kinase/phospha-
tidylinositol-3-kinase (PI3K)/Akt, MAPK and Nek3-
vav2-Rac1 pathways (5). PRLRs are expressed through-
out the hypothalamus in both long- and short-form
isoforms (7–10), notably within neurons known to play
important roles in the control of reproductive hormone
secretion. Curiously, hypothalamic PRLRs have been
shown tobe twice as abundant inwomen than inmen (11).
Although few GnRH neurons, major hypothalamic ef-
fectors of the hypothalamo-pituitary gonadal axis, ex-
press PRLRs (12), they receive ample projections from
regulatory afferents that are PRLR positive: kisspeptin/
neurokinin B/dynorphinA (KNDy) neurons of the arcuate
nucleus (ARC), an essential component of the GnRH
pulse generator; kisspeptin neurons of the anteroventral
periventricular nucleus (AVPV), which are indispensable
for mediating the positive-feedback effects of estradiol
(E2) on GnRH secretion that results in the preovulatory
LH surge; and -aminobutyric acid (GABA)ergic neurons
of the AVPV that regulateGnRHneuron excitability (12).
Indeed, central (13) or peripheral (14) administration of
ovine PRL prevents the occurrence of preovulatory LH
surges in ovary-intact rats and down-regulates ARC kiss-
peptin expression and LH levels in ovariectomized (OVX)
rats (15). Intracerebroventricular (icv) administration of
PRL also dose dependently induces the phosphorylation
of STAT5 in the ARC and AVPV neurons of the OVX rat,
and this effect is amplified by the replacement of E2 (16).
A significant proportion of PRL-receptive ARC neurons
are likely to be KNDy neurons because icv administration
of PRL induced phosphorylated STAT5 expression in
most kisspeptin-immunoreactive cells in this region (15).
Another group of highly PRL-receptive hypothalamic
neurons are involved in the negative feedback of PRL on
its own secretion. Tuberoinfundibular dopaminergic
(TIDA) neurons project from the ARC to the median em-
inence, inwhich they secretedopamine into the longportal
vasculature (17). In addition, rodents possess tuberohy-
pophyseal and periventricular-hypophyseal dopamine
neurons (18), which innervate and secrete dopamine into
short portal vessels within the neural and intermediate
lobes of the pituitary that supply the anterior lobe (17).
Dopamine released by these neuroendocrine systems ac-
tivates dopamine type 2 receptors (D2R) on hypophyseal
lactotropes, tonically inhibiting PRL secretion (19). Cu-
riously, KNDy neurons synapse with TIDA (20) and
periventricular-hypophyseal (21) neurons, and earlier
studies have demonstrated projection of ARC dynorphin-
ergic neurons to TIDA neurons (22). Moreover, recent
evidence suggests that kisspeptin stimulates PRL release
by inhibiting the activity of hypothalamic dopaminergic
neurons in an E2-dependent fashion (23). Thus, the hy-
pothalamic neuroendocrine systems regulating the secre-
tion of gonadotropins and PRL appear to participate in
regulatory cross talk that is subject to modulation by cen-
tral PRL, albeit through yet unknown mechanisms.
LH surges occur after exposure to elevated E2 concen-
trations that stimulate de novo synthesis and release of
progesterone (P4) by specialized neurons and astrocites in
thediencephalon (24–26).Thepositive feedback effects of
E2 and P4 are then conveyed to GnRH neurons by kiss-
peptin neurons of the AVPV (27) subject to appropriate
circadian disinhibition (28). Several lines of evidence im-
plicate central PRL/PRLRsignaling in the regulationof the
LH surge: 1) hyperprolactinemia causes anovulation in
women with microprolactinomas by inhibiting not only
pulsatile LH secretion but also themidcycle LH surge (29,
30); 2) a high proportion of both ARC and AVPV kiss-
peptin neurons express PRLR in female rats (12); 3) lac-
tating mice express 90% less kisspeptin mRNA and 60%
less immunoreactive kisspeptin in AVPV neurons com-
pared with diestrous controls (31, 32). However the role
of central PRL in the regulation of gonadotropin surges
remains obscure. Moreover, it has long been known that
surges of PRL accompany preovulatory LH surges in ro-
dents (33), ruminants (34), and humans (35) alike, and
although the primary role of the PRL surge is apparently
luteolytic (36), its potential effects at the hypothalamic
level have not previously been considered.
To characterize the mechanism by which central PRL
signaling regulates the GnRH pulse generator, we inter-
rogated the hypothesis that GABAergic neurons mediate
PRL-induced suppression of pulsatile LH secretion in
OVX rats primed with low (diestrus d 2) levels of E2
(OVXE2 rats). Because the involvement of central PRL
signaling in the regulation of gonadotropin surges is cur-
rently unknown, we then studied the effect of intracere-
broventricularly administered, 1-9-G129R-hPRL, a
unique pure PRLR antagonist, on the dynamics of LH
surges induced by 17-estradiol-3-benzoate (E2B) and P4
treatment (37) in OVXE2 rats. Finally, we asked
whether acute blockade of central PRLR signaling would
reverse the inhibitory effect of chronic antipsychotic-in-
ducedhyperprolactinemiaon theLHpulse soas toaddress
the hypothesis that chronically elevated PRLacts centrally
to suppress reproductive function.
Materials and Methods
Animals
Adult female Sprague Dawley rats (200–250 g) obtained
from Harlan were housed under controlled conditions (12 h
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light, 12 h darkness, with lights on at 7:00 AM; controlled am-
bient temperature 22°C 2°C) and providedwith standard lab-
oratory chow (RM1; SDS Diets) and water ad libitum. Animals
were group housed (maximum four per enclosure) prior to sur-
gery and housed individually after surgery and during experi-
mentation. All animal procedures were undertaken in accor-
dance with the Animals (Scientific Procedures) Act, 1986 and
were approved by the King’s College London Ethical Review
Panel Committee.
Surgical procedures
All surgical procedures were carried out under general anes-
thesia induced by ketamine (100 mg/kg ip; Pharmacia and Up-
john) coadministered with xylazine (Rompun; 10 mg/kg ip;
Bayer); supplementary injections of ketamine (10 mg, ip) were
administered to maintain anesthesia as required. Each rat was
injected sc with 0.4 mL/kg Duphamox LA antibiotic suspension
(200 mg/mL procaine benzylpenicillin, 250 mg/mL dihydro-
streptomycin-sulfate; Fort Dodge Animal Health) prior to sur-
gery. After each surgical procedure, animals were allowed to
recover from anesthesia on a heated pad until fully conscious.
Postoperative analgesia was provided by means of sc adminis-
tration of carprofen (Rimadyl; 4.4mg/kg; Pfizer Animal Health)
daily for 3 days.
Two weeks before experiments took place, the rats were bi-
laterally OVX and implanted with subcutaneous E2-filled
SILASTIC brand capsules (Dow Corning), which produce cir-
culating concentrations of E2 within the range observed during
the diestrus (d 2) phase of the estrous cycle (35.8 1.2 pg/mL),
as previously described (38). Rats were then implantedwith uni-
lateral guide cannulae (22 gauge; Plastics One), stereotaxically
targeted toward the left lateral cerebral ventricle for microinfu-
sion of pharmacological agents. The stereotaxic coordinates for
implantation were 1.5 mm lateral and 0.6 mm posterior to
bregma and 4 mm below the surface of the dura (39). Correct
cannula placement was confirmed by the observation of gravi-
tational meniscus movement upon insertion of an internal injec-
tion cannula (PlasticsOne)with extension tubingpreloadedwith
artificial CSF (aCSF). A 20-mm stainless steel slotted screw (In-
stecLaboratories)was affixed to the surfaceof the skull posterior
to the guide cannula and both were secured using dental cement
(Simplex Rapid; Dental Filling). The icv guide cannulae were
then fitted with obturators (Plastics One) to maintain patency.
After a 10-day recovery period, the ratswere implantedwith two
custom-made cardiac catheters via the internal jugular veins to
enable simultaneous automated serial blood sampling for pro-
filing of LH levels and manual withdrawal of blood for deter-
mination of PRL levels (40). The catheters were exteriorized at
the back of the head and enclosed within a 30-cm-long light-
weight metal spring tether (Instec Laboratories) secured to the
slotted screw cranial attachment with surgical ligature. The dis-
tal end of the tether was attached to a dummy swivel (Instec
Laboratories), allowing the rat to move freely. After surgery,
animals were housed singly. Experimentation commenced after
a further 3 days of recovery from surgery.
Experimental design
On the morning of experimentation, an icv injection cannula
with extension tubing, preloaded with a combination of drug
solutions, was inserted into the guide cannula. The distal end of
the tubingwas filledwith aCSF. The remainder of the tubingwas
filled with sterile water, with 5 L air separating the water and
aCSF, which allowed the progress of injections to be monitored.
The tubingwas extended outside the cage and connected via one
channel of a two-channel fluid swivel (Instec Laboratories) to a
25-L syringe (Hamilton) prefilled with sterile water to allow
remote microinfusion without disturbing the rats during the ex-
periment.One of the two cardiac catheterswas then attached via
the second channel of the fluid swivel to a computer-controlled
automated blood sampling system, which enables the intermit-
tent withdrawal of small blood samples (25 L) every 5 minutes
for 4–6 hours without disturbing the rats. After removal of each
25-L blood sample, an equal volume of heparinized saline (50
U/mL normal saline; CP Pharmaceuticals) was automatically in-
fused to maintain patency of the catheter and blood volume.
Once connected, the animals were left undisturbed for 1 hour
before blood sampling was initiated (between 9:00 and 10:00
AM).Drug treatmentswere administered after a period of control
blood sampling manually over 5 minutes. Additional blood (50
L) was sampled manually via the second cardiac catheter at
specified time points, and each withdrawal was followed by the
administration (iv) of 50Lheparinized saline. Plasma obtained
by centrifugation of manually withdrawn blood samples was
frozen at 20°C and later assayed to determine concentrations
of PRL by means of a RIA. Automatically sampled blood was
frozen at 20°C and later assayed to determine LH concentra-
tions bymeans of RIA. Tominimize animal suffering in linewith
the Animals (Scientific Procedures) Act, 1986, rats were reused
as part of different treatment groupswithin experiments, but not
between experiments, and were allowed to recover for at least 3
days between bleeding procedures.
Drugs and hormones
1-9-G129R-hPRL, recombinant human PRL with Gly129
replacedwithArg and nineN-terminal residues deleted, is a pure
PRLR antagonist (41). 1-9-G129R-hPRL was expressed in
Escherichia coli as inclusion bodies, using the pT7L expression
vector, as described previously (42), and purified using an ion
exchange column (Hi Trap Q-Sepharose; GE Healthcare Life
Sciences). Lyophilized aliquots of 1-9-G129R-hPRL were re-
constituted with sterile water and diluted with aCSF. Recombi-
nant rat PRL (ABC2856; Source BioScience Life Sciences) was
reconstituted from lyophilized stocks with sterile water and di-
luted with aCSF. The selective GABAAR antagonist bicuculline
(1(S),9(R)-()-bicuculline methbromide; Sigma-Aldrich) was
dissolved in sterile water and diluted with aCSF. The D2R an-
tagonist sulpiride [(S)-()-sulpiride; sc-258111; Santa Cruz Bio-
technology] was solubilized with 1 M tartaric acid (L-()-tar-
taric acid (sc-218622; Santa Cruz Biotechnology) and diluted
with saline, the final concentration of tartaric acid being 10mM.
Effect of central administration of PRL on pulsatile
LH secretion in OVXE2 rats
A total of 7 OVXE2 rats were used in this experiment; a
crossover design ensured that each animal was randomly as-
signed to a treatment group and subsequently to its counterpart
control group. The treatment groups were as follows: 1-9-
G129R-hPRL (antag) aCSF (n 4), bicuculline (bic) aCSF
(n  3), aCSF  PRL (n  5), antag  PRL (n  7), and bic 
PRL (n 5). All treatments were administered icv in a volume of
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4 L aCSF. One hour 40 minutes into a 6-hour blood sampling
procedure, rats were pretreated with 20 g 1-9-G129R-hPRL,
500 ng bicuculline, or 4 L aCSF. Twenty minutes later, the
animals receiveda further icv injectionof5gPRLor4LaCSF.
Additional blood samples for measurement of PRL levels were
withdrawn at 60, 135, 150, 180, 240, and 360 minutes relative
to the time when the automated blood sampling was initiated.
Effect of hypothalamic PRLR antagonism on LH
and PRL surges induced by E2B and P4 treatment
in OVXE2 rats
To induce concomitant LH and PRL surges, OVXE2 rats
were subjected to gonadal steroid priming according to a pro-
tocol described previously (43). A total of 10 animals were in-
jected (sc) with 2 g E2B (Sigma-Aldrich) in 100 L arachis oil
(Sigma-Aldrich) at approximately 9:00 AM daily for 2 days. At
9:00 AM on the morning of the experiment, the rats received 500
g P4 (Sigma-Aldrich) in 100 L arachis oil (Sigma-Aldrich), sc.
One hour 30 minutes later, a 1-hour control blood sampling
procedurewas initiated. Three hours after the P4 administration,
the rats were injected (icv) with 20 g 1-9-G129R-hPRL in 4
L aCSF (n 7) or 4 L aCSF (n 3). One hour later (240 min
after P4 administration), a further 6 hours of serial blood sam-
pling was initiated. At the same time, a 3-hour infusion of 60 g
1-9-G129R-hPRL in 12 L aCSF (n 7) or 12 L aCSF (n
3), driven by a syringe pump (PHD 2000; Harvard Apparatus),
was started. Additional blood samples for measurement of PRL
levels were withdrawn at 60, 120, 240, 300, 360, 420, 480, 540,
and 600 minutes relative to the time of P4 administration.
Effect of hypothalamic PRLR antagonism on
pulsatile LH secretion in chronically
hyperprolactinemic OVXE2 rats
A total of 15 animals were used in this experiment. To render
OVXE2 rats chronically hyperprolactinemic, sc injections of
sulpiride (5 mg/kg in 450 L 10 mM tartaric acid) were given at
9:00 AM and 5:00 PM hours daily for at least 11 days prior to
experimentation as well as on the day of the experiment (n 8).
This protocol has been previously demonstrated to induce
chronic hyperprolactinemia in OVXE2 rats (16). Control rats
(n 7) received 450 L 10mM tartaric acid (sc) at 9:00 am and
5:00 PMdaily for at least 11 days prior to experimentation aswell
as on the day of the experiment. Rats were subjected to a 4-hour
serial blood sampling procedure that commenced at 10:00 AM.
The animals received four consecutive icv injections of 20 g
1-9-G129R-hPRL in 4 L aCSF or 4 L aCSF at 20-minute
intervals between 12:00 and 3:00 PM. Additional blood samples
for measurement of PRL levels were withdrawn hourly between
9:30 AM and 5:30 PM. The experiment followed a crossover de-
sign whereby all animals received 1-9-G129R-hPRL and six of
the eight sulpiride-treated rats and five of the seven control rats
were randomly selected to receive aCSF during separate trials at
least 3 days apart.
Hormone RIA
Double-antibody RIAs supplied by the National Hormone
andPeptide Program (Harbor-UCLAMedicalCenter, Torrance,
California) were used to determine LH and PRL concentrations
in the 25-L whole-blood samples and 10-L plasma samples,
respectively. Values are expressed in terms of the standard prep-
arations NIDDK-rPRL-RP-3 and NIDDK-rLH-RP-3. The limit
of sensitivity of the LH RIA was 0.093 ng/mL and the inter- and
intraassay variations were 6.8% and 8.0%, respectively. The
limit of sensitivity of the PRLRIAwas 4.9 ng/mL. The intraassay
variation was 8.9% and all PRL values were obtained from a
single assay.
Data analysis
Detection of LH pulses was facilitated by the use of the al-
gorithm ULTRA (44). Two intraassay coefficients of variation
(2  cv) of rat plasma pools, with LH concentrations falling
within the log phase of the LH RIA standard curve were used as
the reference threshold for pulse detection. The effect of treat-
ments on LH pulse frequency was analyzed by comparing the
meanLHpulse interval in the 2-hour period preceding treatment
with that in 2-hour posttreatment period(s). The period duration
(in minutes) was divided by the number of LH pulses detected in
each of these periods to give the appropriate LH pulse interval.
When there were no LH pulses evident during the first 2-hour
posttreatment period, the LH pulse interval assigned to this pe-
riod was taken as the interval from the onset of treatment to the
first LH pulse in the second 2-hour posttreatment period. The
significance of the effect of treatments on LH pulse frequency
was compared with the respective negative control group at the
same time points as well as with the mean pulse interval during
the 2-hour pretreatment period in the same treatment group.
Statistical significancewas tested using a one-wayANOVAwith
Bonferroni post hoc test. P 	 .05 was considered statistically
significant. Values given in the text and figures represent mean
(SEM).
PRL levels in all experiments, as well as surge-like LH levels,
were compared using a two-way ANOVA with repeated mea-
sures (influence of time and treatment) with Holm-Sidak pair-
wise multiple comparison. Overall significance threshold was
P 	 .05. In addition, cumulative changes in PRL and LH levels
were expressed as area under the curve for individual treatment
groups, which were compared using a paired, two-tailed Stu-
dent’s t test (two groups) or a one-wayANOVAwith Bonferroni
post hoc test (more than two groups). P 	 .05 was considered
statistically significant. Values given in the text and figures rep-
resent mean (SEM).
Results
Effect of central administration of PRL on pulsatile
LH secretion in OVXE2 rats
No effect of icv 1-9-G129R-hPRL pretreatment on
the LHpulsewas observed in rats administeredwith aCSF
(representative example in Figure 1A), at least during the
first 4hours20minutes after the injection.Bicuculline also
had no significant effect on pulsatile LH secretion (repre-
sentative example in Figure 1B). Administration (icv) of
PRL suppressed pulsatile LH secretion for a period of 1–2
hours (representative examples in Figure 1, C and D). No
LH pulses were detectable during the period of PRL-in-
duced suppression, the onset of which was immediate
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upon administration in three of the five animals (repre-
sentative example in Figure 1C) and delayed by 10–60
minutes in two of the five animals (representative example
in Figure 1D).A gradual recovery of theLHpulsewas seen
in the second 2 hours after the injection in all five animals.
Pretreatment with either 1-9-G129R-hPRL (representa-
tive example in Figure 1E), or bicuculline (representative
example in Figure 1 F) completely blocked the PRL-in-
duced suppression of the LH pulse. The results of this
experiment are summarized in the histogram (Figure 1G).
None of the treatments had a significant effect on circu-
lating PRL levels, which fluctuated between 20 and 100
ng/mL in all treatment groups (Figure 1H).
Effect of hypothalamic PRLR antagonism on LH
and PRL surges induced by E2B and P4 treatment
in OVXE2 rats
Treatment of OVXE2 rats with E2B and P4 induced
afternoon surges of LH (Figure 2A) and PRL (Figure 2B).
LH levels increased steadily between 300 and 480minutes
after P4 (2:00 PM and 5:00 PM, respectively) in all rats,
plateauing at approximately 15 ng/mL in rats treatedwith
aCSF and 27 ng/mL in 1-9-G129R-hPRL-treated rats
and subsequently declining. The magnitude of the LH
surge was significantly greater in rats treated with 1-9-
G129R-hPRL than in aCSF-treated controls (Figure 2A).
Treatment with 1-9-G129R-hPRL did not alter the time
of LH surge onset. PRL levels in aCSF-treated controls
rose significantly above baseline at 420 minutes after P4
(4:00 PM), remaining elevatedat480minutes (5:00 PM) and
declining thereafter (Figure 2B). In rats administered with
1-9-G129R-hPRL, PRL levels remained at baseline
throughout the blood sampling procedure (Figure 2B).
Effect of hypothalamic PRLR antagonism on
pulsatile LH secretion in chronically
hyperprolactinemic OVXE2 rats
Chronic sulpiride-induced hyperprolactinemia per-
turbed the regularity of LH pulses and increased the du-
ration of the interval between them from approximately
28minutes tomore than45minutes (Figure3,A–E).Acute
treatment with 1-9-G129R-hPRL had no detectable ef-
fect on LH pulse frequency, neither in rats administered
with vehicle nor in those treated with sulpiride (Figure 3,
A–E). PRL levels in chronic sulpiride animals (200–1000
ng/mL) were significantly higher than those in chronicFigure 1. Effect of central administration of PRL on pulsatile LH
secretion in OVXE2 rats. Representative LH profiles demonstrating
the effect of icv administration (long arrows) of vehicle (aCSF; A and B)
or PRL (C–F), after icv pretreatment (short arrows) with one of the
following: 1) the pure PRLR antagonist, 1-9-G129R-hPRL (antag; A
and E); 2) the selective GABAAR antagonist, bicuculline (bic; B and F);
or 3) vehicle (aCSF; C and D) on pulsatile LH secretion in OVXE2 rats.
The suppression of the LH pulse by PRL was blocked by both the PRLR
and the GABAAR antagonists, as summarized in panel G. None of the
Figure 1 (Continued). treatments significantly affected PRL secretion
(H). The histogram (G) depicts group means (SEM). White numbers
within the black bars (G) denote the size of the treatment groups. *,
P 	 .05 vs 2-hour baseline control period within the same treatment
group as well as vs the same 2-hour period within all other treatment
groups.
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vehicle controls (	200 ng/mL) throughout the blood-
sampling procedure (Figure 3, F and G). In sulpiride-
treated animals, PRL levels were highest at 9:30 AM (30
min after the morning sulpiride injection), declining
through the afternoon and increasing again at 5:30 PM (30
min after the evening sulpiride injection). PRL levels in
vehicle-treated controls did not change significantly
through the blood-sampling procedure, although a non-
significant trend whereby PRL levels were higher at 9:30
AM than at subsequent time points was observed. Again,
acute administration of 1-9-G129R-hPRL had no effect
on PRL levels in both vehicle- and sulpiride-treated rats
(Figure 3, F and G).
Discussion
In an attempt to broaden the understanding of the roles of
central PRL/PRLR signaling in regulating the reproduc-
tive system, we are the first to report that icv administra-
tion ofOVXE2 ratswith exogenous PRL suppresses pul-
satile LH secretion in a GABAAR-dependent fashion. We
have also demonstrated that central PRL-induced sup-
pressionof theLHpulse is fully blockedby the antagonism
of central PRLR.Taken together, our findings suggest that
endogenous hypothalamic GABA release is rapidly trig-
gered in response to exogenous PRL activation of central
PRLR and that signaling throughGABAAR is essential for
the LH pulse inhibition induced by central PRL adminis-
tration. However, the PRL-receptive GABAergic neurons
and their efferent targets that modulate LH secretion re-
main to be identified. An equal dose of PRL to that used
in experiments we describe here has previously been dem-
onstrated to potently induce cFos (45) and phosphory-
lated STAT5 (pSTAT5) (46) immunoreactivity in several
hypothalamic nuclei known to contain GABAergic neu-
rons, including the ARC and AVPV. Of these, the ARC
populationwas identified to express tyrosine hydroxylase
(an enzyme involved in the catalysis of the rate limiting
stage of catecholamine synthesis) (45), suggesting a do-
paminergic phenotype. However, a wealth of evidence in-
dicates that some ARC tyrosine hydroxylase neurons, in-
cluding TIDA neurons, are also GABAergic (47–51).
Arcuate GABA signaling is known to negatively regu-
late pulsatile LH secretion: microimplantation of crystal-
line GABA in the ARC of OVX rats suppresses LH pulse
frequency andmeanLH levels (52). This effect ismediated
by GABAAR because administration of the selective
GABAAR agonist, muscimol, suppresses both the electro-
physiological (multiunit activity volleys in themediobasal
hypothalamus) and endocrine (pulsatile LH secretion)
correlates of the GnRH pulse generator in OVX rats (53).
More recently GABA has been shown to inhibit the spon-
taneous firing activity of murine KNDy neurons (54) and
central agonism of GABAAR, but not GABABR, attenu-
ated kisspeptin-induced gonadotropin secretion in male
rats (55). Central PRL administration has recently been
shown to suppress ARC kisspeptin expression and mean
LH levels in OVX rats (15). These findings are in agree-
ment with the inhibition of kisspeptin mRNA and immu-
noreactivity in the ARC, as well as the suppression of
Figure 2. Effect of hypothalamic PRLR antagonism on LH and PRL surges induced by E2B and P4 treatment in OVXE2 rats. Comparison of the
dynamics of LH (A) and PRL (B) secretion in OVXE2 rats treated with surge-inducing levels of E2B and P4 and administered icv with the pure PRLR
antagonist, 1-9-G129R-hPRL (antag), or vehicle (aCSF). Rats received a bolus injection (arrows) of 20 g 1-9-G129R-hPRL in 4 L aCSF or 4 L
aCSF alone, followed by a 3-hour infusion (horizontal bars) of 60 g 1-9-G129R-hPRL in 12 L aCSF or 12 L aCSF alone. Administration of 1-
9-G129R-hPRL augmented the magnitude of the LH surge (A) and blocked the concomitant PRL surge (B). Insert in panel A compares the
cumulative LH secretion in the two treatment groups throughout the experiment, expressed as the area under the curve. Numbers within the
vertical bars (insert in A) denote the size of the treatment groups. *, P 	 .05 vs corresponding value in aCSF-treated control group. Values plotted
in scatter graphs (A and B) are group means (SEM); #, first value in the time series that is significantly different (P 	 .05 vs corresponding value in
aCSF treated control group); all subsequent values are also significantly different from controls.
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pulsatile LH secretion, reported throughout lactation in
suckled OVX rats (56, 57), which is well known to mark-
edly elevate circulating PRL (58) and CSFGABA (59) lev-
els.However, no differences inARCGABA turnoverwere
detected between diestrous and lactating rats, despite el-
evated PRL and suppressed LH secretion in the latter (60),
which suggests that PRL-induced activation of GABAer-
gic signaling might occur elsewhere. GABAergic neurons
of the AVPV, unlike those in surrounding nuclei, are
highly PRL receptive (12) and are known to innervate
GnRH perikarya (61). Both GABAAR (62) and GABABR
(63, 64) have been shown to be expressed by GnRH neu-
rons. However, it has been reported that the GABAergic
signal supplied to GnRH neurons by the AVPV is pre-
dominantly stimulatory (61). These conundrums necessi-
tate investigation into the anatomy and function of PRL-
responsive GABAergic neurons we implicate in the
suppression of pulsatile LH secretion induced by acute
central administration of PRL.
Wedidnot detect changes in endogenousPRL secretion
in response to acute central administration of exogenous
PRL. Neither did the acute 1-9-G129R-hPRL blockade
of central PRLR influence PRL secretion. This is perplex-
ing in light of extensive evidence for the short-loop neg-
ative feedback effect of PRL on its own secretion (65–68).
However, classic studies by Moore and colleagues (69–
71) evidenced consistently delayed feedback effects of cen-
tral or peripheral PRL administration in rats, as revealed
Figure 3. Effect of hypothalamic PRLR antagonism on pulsatile LH secretion in chronically hyperprolactinemic OVXE2 rats. Representative LH
profiles demonstrating the effect of icv administration (short arrows) of vehicle (aCSF; A, C) or the pure PRLR antagonist, 1-9-G129R-hPRL (antag;
B and D) on pulsatile LH secretion in OVXE2 rats treated (sc; long arrows) with the D2R antagonist, sulpiride, twice daily for at least 11 days to
induce chronic hyperprolactinemia (C and D) or normoprolactinemic controls (A and B) that received vehicle (10 mM tartaric acid). Administration
of 1-9-G129R-hPRL had no effect on the prolongation of the LH pulse interval induced by chronic hyperprolactinemia, as summarized in panel E.
1-9-G129R-hPRL also had no effect on PRL secretion in hyperprolactinemic and normoprolactinemic rats (F and G). Values plotted in the scatter
graph (F) are group means (SEM). Histograms (E and G) depict group means (SEM). Numbers within the white bars (E and G) denote the
treatment group sizes. *, P 	 .05 vs the corresponding value within the normoprolactinemic control group; #, P 	 .05 vs the preinjection period in
the same treatment group.
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by median eminence dopamine synthesis and turnover in-
creasing significantly as long as 12–24 hours after treat-
ment. Moore and colleagues (72, 73) subsequently re-
vealed amore rapid activation of PRL feedback in animals
with basal PRL secretion suppressed by bromocriptine
(D2R agonist) treatment or hypophysectomy, although
even that was detectable only after 4 hours. Thus, the
absence of a short-loop negative feedback effect of central
PRLR activation, or that of their blockade, on circulating
PRL levels in normoprolactinemic OVXE2 rats within
the examined time frame is expected.
Having established a tentative mechanism for PRL-in-
duced suppression of pulsatile LH secretion and con-
firmed the pure antagonistic properties of 1-9-G129R-
hPRL in our experimental setting, we interrogated the
hypothesis that PRL found endogenously within the cen-
tral nervous systemmodulates LH and PRL surges. There
have been several prior attempts to investigate the involve-
ment of central PRL signaling in the regulation of the LH
surge (16, 74, 75). However, these studies involved the
augmentation of PRL signaling beyond that found under
physiologic conditions. Here we demonstrate that block-
ade of central PRLR augments the magnitude of the LH
surges induced by E2B and P4 treatment, without altering
the time of its onset, and blocks the concomitant PRL
surge in normoprolactinemicOVXE2 rats. Our findings
raise the possibility that the endogenous PRL surge pro-
vides restraint of the LH surge by hindering hyperactiva-
tion of hypothalamic circuitry involved in its induction.
Indeed, there appears to be an inverse relationship be-
tween the magnitudes of the LH and PRL surges, as re-
vealed by pharmacological manipulation of P4 signaling
(76). However, complete suppression of endogenous PRL
surges by treatment with bromocriptine had no effect on
the concomitant LH surge in proestrous rats (77). Hence,
the disinhibition of LH surge magnitude after central 1-
9-G129R-hPRL administration is unlikely to be conse-
quential to PRL surge suppression per se but is perhaps
rather the effect of restrictedaccessof residual endogenous
PRL to central PRLR.
Because few GnRH neurons express PRLR (12), the
disinhibition of LH surge magnitude resulting from
the acute antagonism of central PRLR could involve the
blockade of direct prolactinergic suppression of AVPV
kisspeptin neurons and/or that of prolactinergic stimula-
tion of afferents that regulate the excitability of GnRH
neurons, eg, GABAergic AVPV neurons (12, 78, 79). Al-
ternatively, blockade of central PRLR (and/or that of the
PRL surge) by 1-9-G129R-hPRL could augment the
magnitudeof theLHsurgebydiminishingPRL-stimulated
dopaminergic activity in the hypothalamus (80). Indeed,
more than a third of GnRH neurons have been demon-
strated to be subject to tonic inhibition by dopamine (78)
that could originate from ARC TIDA neurons (81, 82) or
GABAergic kisspeptin neurons in the AVPV (79, 83). Fur-
thermore, P4 is known to allosterically potentiate the ef-
fects of GABA on GABAAR (84). Although all animals
received the same dose of exogenous P4, antagonism of
central PRLR could have interfered with E2B-induced ste-
roidogenesis by hypothalamic astrocytes (24–26), effec-
tively enhancing the amplitude of the LH surge (76). In-
deed, neurosteroid biosynthesis has been shown to be
regulated by PRL in newts (85), although this phenome-
non has not yet been explored in mammals. Notwith-
standing, studies in mammals implicate GABA/GABAAR
signaling inmodulatingneurosteroidogenesis (86, 87).Be-
cause we witnessed the essential role of hypothalamic
GABA/GABAAR signaling inmediating the effects of PRL
on LH secretion, evidence substantiated by the apparently
PRL-receptive nature of hypothalamic GABA neurons
(12), it is logical to speculate that PRL regulation of de
novo progesterone synthesis by neurons and glia could be
mediated by GABAergic afferents (87).
Another potential mechanism that might underlie the
1-9-G129R-hPRL-induced amplification of the LH
surge involves changes in the sensitivity of noradrenergic
neurons of the locus coeruleus (LC) to P4. These neurons
down-regulate their expressionofP4 receptoronproestrus
afternoon (88), concomitant with the PRL surge and in-
creased cFos expression in the LC (89), and are known to
provide stimulatory noradrenergic input to GnRH neu-
rons during the LH surge (90, 91). Because no data are
available on the PRL sensitivity of the noradrenergic LC,
it is unclear at what level PRL or 1-9-G129R-hPRL
would be able to modulate these pathways. However, re-
cent evidence again implicates the highly PRL-receptive
(12) AVPVneurons (92). These hypotheses require urgent
investigation.
Although pretreatment with 1-9-G129R-hPRL aug-
mented the magnitude of the LH surge, it had no effect on
its time of onset. Similar observations were reported in
GnRH-primed, prostaglandin F2-treated lactating yaks,
in which suppression of PRL secretion with quinagolide
(another D2R agonist) augmented the magnitude of LH
surges induced byGnRHadministration but did not affect
its onset (93). The onset of the preovulatory LH surge in
nocturnal rodents is timed to coincide with the reduction
in daylight by the circadian pacemaker within the supra-
chiasmatic nucleus (SCN) the hypothalamus (94). Argi-
nine vasopressin neurons of the SCN markedly increase
the sensitivity of GnRH neurons to stimulation by AVPV
kisspeptin neurons and disinhibit GnRH secretion from
tonic suppression by RF-amide related peptide 3 neurons
in a time-gated fashion (95). We expect the association
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between disruption of central PRL/PRLR signaling and
augmentation of the magnitude of the LH surge without a
change in its timing, which we and others (93) have dem-
onstrated, to reflect the suppressive effect of a centrally
penetrating PRL tone on the ability of AVPV kisspeptin
neurons to elicit GnRH release during a timewindowgov-
erned by neurons of the SCN, without affecting the time-
restricting function of the SCN neurons per se. Indeed,
AVPVkisspeptin neurons (12), but not SCNneurons (96),
have been shown to express PRLR, confirming that the
circadian pacemaker is not subject to regulation by central
prolactin.
The absence of PRL surges in 1-9-G129R-hPRL-
treated animals is perhaps best explained by the inability
of centrally transported PRL to activate the positive oxy-
tocin-PRL feedback loop recently suggested by Kennett
and McKee (97). In our experiments, both control and
1-9-G129R-hPRL-treated rats were exposed to P4 levels
capable of suppressing TIDA neuron dopamine output
and therebypermissive toPRLsurge generation (98–101).
However, blockadeof central PRLRpresumably extended
to those expressed by hypothalamic oxytocin neurons
(102) that secrete oxytocin in response to elevatedE2 (103,
104) and PRL (97, 105) levels. Oxytocin is a potent PRL
secretagogue (106, 107), its stimulatory effect on PRL se-
cretion is augmentedduringproestrus (108), andoxytocin
antagonists block PRL surges (109–111). Thus, 1-9-
G129R-hPRL-treated, but not control rats,were probably
deprived of oxytocinergic stimulation of surge release of
PRL. An alternative hypothesis implicates GABA/
GABAAR signaling: central administration of bicuculline
has been shown to block afternoon surges of PRL by sup-
pressing the activity of TIDA neurons (112) and to aug-
ment LH surge magnitude without advancing its onset
(113) in rats. Furthermore, we have shown that icv pre-
treatment with either 1-9-G129R-hPRL or bicuculline
restores LH pulsatility suppressed by acute central PRL
administration, confirming the close functional relation-
ship between hypothalamic PRL/PRLR and GABA/
GABAARsignaling implied by the PRL-receptive anatomy
of GABAergic afferents to GnRH neurons (12).
These findings are consistent with a role for endoge-
nous PRL in attenuating the extent of GnRH neurosecre-
tion underlying surges of LH by directly stimulating hy-
pothalamic release ofGABAand highlight the importance
of central PRL/PRLR signaling in stimulating its own se-
cretion through positive-feedback effects on hypotha-
lamic GABA neurons (that suppress TIDA inhibition of
PRL secretion) and/or oxytocin neurons (which stimulate
pituitary PRL release). Future studies should confirm
whether the mechanism of 1-9-G129R-hPRL-induced
blockade of the PRL surge involves the disruption of pos-
itive oxytocin-PRL feedback and/or that of GABAergic
disinhibition of PRL secretion from the dopamine tone.
Hyperprolactinemia, including that induced by anti-
psychotic treatment, suppresses reproductive function
and, paradoxically, the only effective means of treatment
are dopamine receptor agonists, which exacerbate psy-
chotic symptoms and are therefore contraindicated (114–
116). Having demonstrated that central administration of
PRL inhibits the pulsatile secretion of LH in normopro-
lactinemic OVXE2 rats, we reasoned that central PRLR
might resemble a useful therapeutic target for the man-
agement of reproductive defects caused by antipsychotic-
induced hyperprolactinemia. To test this hypothesis, we
administered OVXE2 rats receiving long-term twice-
daily sulpiride treatmentwith1-9-G129R-hPRL into the
cerebroventricular system.We confirmed previous obser-
vations (16) that chronic administration of sulpiride is an
effective means of inducing hyperprolactinemia and re-
ducing the frequency of LHpulses inOVXE2 rats.How-
ever, four consecutive injections of 20 g 1-9-G129R-
hPRLgiven every20minutesneither altered thePRL levels
elevated by chronic exposure to sulpiride nor reversed the
inhibitory effect of hyperprolactinemia on LH pulse fre-
quency. These data demonstrate that acute blockade of
central PRLR is not sufficient to reverse the effect of long-
term hyperprolactinemia on pulsatile LH secretion.
Relative to the long-term changes in the chemistry of
ARC neurons induced by chronic hyperprolactinemia
(117), the limited duration of PRLR antagonism provided
by acute icv administration of 1-9-G129R-hPRL might
be sufficient to transiently disinhibit ARC kisspeptin ex-
pression from tonic PRL-induced suppression (15). How-
ever, if that were the case, such changes would be detect-
able only several hours after treatment and would not
necessarily restore the LHpulse to frequencies observed in
normoprolactinemic controls. In the context of the wider
literature, these data suggest that themechanismbywhich
chronic hyperprolactinemia perturbs reproductive func-
tion involves long-term genomic changes in the cross talk
between populations of PRL-sensitive hypothalamic neu-
rons, which are not reversible by the acute blockade of
central PRLR. To further address the contribution of cen-
tral PRLR to the suppressive effects of hyperprolactinemia
on reproductive function, selective inducible knockdown
of PRLR within discrete hypothalamic nuclei in chroni-
cally hyperprolactinemic rats is advised.
In summary, we have shown that the activation of cen-
tral PRLR leads to the acute suppression of LH pulsatility
and demonstrated that GABA/GABAAR signaling is an
indispensable part of the mechanism involved. These data
raise the possibility that PRL-receptive GABAergic neu-
rons may mediate inhibition of fertility attributed to ele-
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vated PRL. Moreover, we provide the first evidence that
central PRL signaling provides tonic inhibition of the LH
surge and is necessary for the generation of the PRL surge
that tends to coincide with it. Finally, we report a lack of
effect of acute blockade of central PRLR on pulsatile LH
secretion andPRL levels in hyperprolactinemic rats. These
observations assist the interpretationof andprovidea con-
text to previous reports on the role of PRL in modulating
hypothalamic circuits important in regulatingmammalian
reproduction.
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